IBRX · ImmunityBio Inc
United States · RS rating 98 · As of 2026-10-14
| Price | 9.91 USD |
|---|---|
| 1-day change | +1.1% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 97 / 94 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 53 / 57 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | +19.4% |
| Distance from 52-week high | +14.2% |
| Market cap (USD) | $8.5B |